. 2009 May;16(3):8–20. doi: 10.3747/co.v16i3.377

TABLE II.

Single-agent taxane compared with non-taxane/non-anthracycline regimens

Reference	Phase	Treatment arms	Pts (n)	Medianpfs(months)	Medianttp(months)	Medianos(months)	orr(%)
Bonneterre et al., 1997²¹	iii	Docetaxel	86	nr	6.5	16	43
Bonneterre et al., 1997²¹	iii	Vinorelbine/5-fu	90	nr	5.1	15	38.8
Nabholtz et al., 1999²²	iii	Docetaxel	203	16^a	19^a	11.4^a	30^a
Nabholtz et al., 1999²²	iii	Mitomycin/vinblastine	189	10	11	8.7	11.6
Sjöström et al., 1999²³	iii	Docetaxel	143	nr	6.3^a	10.4	42^a
Sjöström et al., 1999²³	iii	Methotrexate/5-fu	139	nr	3.0	11	21
Dieras et al., 1995²⁴	ii	Paclitaxel	36	9.1	3.5^b	12.7	15
Dieras et al., 1995²⁴	ii	Mitomycin	36	6.7	1.6	8.4	5
Talbot et al., 2002²⁵	ii	Paclitaxel	19	nr	3.1	9.4	36
Talbot et al., 2002²⁵	ii	Capecitabine	22	nr	3.0	7.6	26

^{^a}

p < 0.01.

^{^b}

p < 0.05.

Pts = patients; pfs = progression-free survival; ttp = time to progression; os = overall survival; orr = overall response rate; nr = (not reported); 5-fu = 5-fluorouracil.